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ABSTRACT
In the last decade, as a result of the widespread use of PCR and DNA sequencing, 16S rDNA sequencing
has played a pivotal role in the accurate identiﬁcation of bacterial isolates and the discovery of novel
bacteria in clinical microbiology laboratories. For bacterial identiﬁcation, 16S rDNA sequencing is
particularly important in the case of bacteria with unusual phenotypic proﬁles, rare bacteria, slow-
growing bacteria, uncultivable bacteria and culture-negative infections. Not only has it provided
insights into aetiologies of infectious disease, but it also helps clinicians in choosing antibiotics and in
determining the duration of treatment and infection control procedures. With the use of 16S rDNA
sequencing, 215 novel bacterial species, 29 of which belong to novel genera, have been discovered from
human specimens in the past 7 years of the 21st century (2001–2007). One hundred of the 215 novel
species, 15 belonging to novel genera, have been found in four or more subjects. The largest number of
novel species discovered were of the genera Mycobacterium (n = 12) and Nocardia (n = 6). The oral
cavity ⁄dental-related specimens (n = 19) and the gastrointestinal tract (n = 26) were the most important
sites for discovery and ⁄ or reservoirs of novel species. Among the 100 novel species, Streptococcus
sinensis, Laribacter hongkongensis, Clostridium hathewayi and Borrelia spielmanii have been most thoroughly
characterized, with the reservoirs and routes of transmission documented, and S. sinensis, L. hongkong-
ensis and C. hathewayi have been found globally. One of the greatest hurdles in putting 16S rDNA
sequencing into routine use in clinical microbiology laboratories is automation of the technology. The
only step that can be automated at the moment is input of the 16S rDNA sequence of the bacterial isolate
for identiﬁcation into one of the software packages that will generate the result of the identity of the
isolate on the basis of its sequence database. However, studies on the accuracy of the software packages
have given highly varied results, and interpretation of results remains difﬁcult for most technicians, and
even for clinical microbiologists. To fully utilize 16S rDNA sequencing in clinical microbiology, better
guidelines are needed for interpretation of the identiﬁcation results, and additional ⁄ supplementary
methods are necessary for bacterial species that cannot be identiﬁed conﬁdently by 16S rDNA
sequencing alone.
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INTRODUCTION
One and a half centuries after the 22-year-old
Charles Darwin’s 5-year voyage on HMS Beagle,
the analysis of small rDNA gene sequences is
another important landmark in the study of the
evolution and classiﬁcation of living organisms.
Traditionally, living organisms were classiﬁed,
according to similarities and differences in their
phenotypic characteristics, into prokaryotes and
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eukaryotes, and these were in turn further clas-
siﬁed into various kingdoms, phyla, classes,
orders, families, genera and species. However,
objective taxonomic classiﬁcation by these meth-
ods can be difﬁcult because of variations in
phenotypic characteristics. Three decades ago,
Carl Woese and others started to analyse and
sequence the 16S rDNA genes of various bacteria,
using DNA sequencing, a state-of-the-art technol-
ogy at that time, and used the sequences for
phylogenetic studies [1,2]. The invention of PCR
and automated DNA sequencing two decades
ago, and subsequent work on 16S rDNA sequenc-
ing of bacteria, as well as 18S rDNA sequencing of
eukaryotes, has led to the accumulation of a vast
amount of sequence data on the rDNA genes of
the smaller subunit of the ribosomes in a large
number of living organisms. Comparison of these
sequences has shown that the rDNA gene
sequences are highly conserved within living
organisms of the same genus and species, but
that they differ between organisms of other
genera and species. Using these rDNA gene
sequences for phylogenetic studies, three
domains of life, Archaea, Bacteria and Eukarya,
as opposed to the traditional classiﬁcation of
living organisms into prokaryotes and eukaryotes
only, were described [3].
Among the three domains of life, the largest
amount of rDNA gene sequencing work concerns
bacteria. Using 16S rDNA sequences, numerous
bacterial genera and species have been reclassi-
ﬁed and renamed, classiﬁcation of uncultivable
bacteria has been made possible, phylogenetic
relationships have been determined, and the
discovery and classiﬁcation of novel bacterial
species has been facilitated. In the last decade,
sequencing of various bacterial genomes and
comparison between genome and 16S rDNA gene
phylogeny has conﬁrmed the representativeness
of the 16S rDNA gene in bacterial phylogeny [4].
As a result of the increasing availability of PCR
and DNA sequencing facilities, the use of 16S
rDNA sequencing has not been limited to
research purposes, but has also been exploited
in clinical microbiology laboratories. Accurate
identiﬁcation of bacterial isolates is one of the
most important functions of clinical microbiology
laboratories. On a patient-to-patient basis, accu-
rate identiﬁcation is crucial in determining
whether the isolate is causing genuine infection
or is simply a colonizer or contaminant, the choice
and duration of antibiotic treatment, and the
appropriate infection control procedures. On a
population scale, accurate identiﬁcation is impor-
tant in analysing the epidemiology, antibiotic
resistance patterns, treatment plans and outcomes
of infections associated with a particular bacte-
rium. Traditionally, identiﬁcation of bacteria in
clinical microbiology laboratories was performed
using phenotypic tests, including Gram smear
and biochemical tests, taking into account culture
requirements and growth characteristics. How-
ever, these methods of bacterial identiﬁcation
have major limitations. First, organisms with
biochemical characteristics that do not ﬁt into
the patterns of any known genus and species are
occasionally encountered. Second, they cannot be
used for uncultivable organisms. Third, identiﬁ-
cation of some particular groups of bacteria, such
as anaerobes and mycobacteria, would require
additional equipment and expertise, which are
not available in most clinical microbiology labo-
ratories. Using 16S rDNA sequencing, these prob-
lems can be overcome by a single technology,
which also facilitates the discovery of novel
genera and species.
In this article, the use of 16S rDNA sequencing
in clinical microbiology laboratories for bacterial
identiﬁcation, the discovery of novel bacterial
genera and species, the detection of uncultivable
bacteria and the diagnosis of culture-negative
infections are reviewed. Automation of 16S rDNA
sequencing and the usefulness and limitations of
16S rDNA sequencing in clinical microbiology
laboratories are also discussed. The technological
aspects of 16S rDNA sequencing are not included
in this review.
METHODS
In the section on ‘Novel bacterial genus and species discovery’,
novel species discovered from human specimens that were
reported during the ﬁrst 7 years of the 21st century (2001–
2007) in the English literature are reviewed. For initial
screening, ‘gen. nov.’ and ‘sp. nov.’ were used as the key
words for a Medline search. The results were manually
screened for novel bacterial species isolated from human
specimens, regardless of the criteria used for their deﬁnition.
Bacteria that were discovered only in non-human specimens
were excluded. Bacteria that were discovered, characterized
and named before 2001, but were renamed after 2001 (e.g.
Streptococcus lutetiensis and S. pasteurianus [5]), and those that
were further subclassiﬁed (e.g. S. pseudopneumoniae [6])
because of acquisition of new information such as 16S rDNA
sequences or phenotypic test results, were also not included.
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Additional reports on infections associated with each of the
novel species isolated from human specimens, as well as those
concerning their isolation from non-human specimens, were
searched. All novel species that have been found in four or
more subjects are presented.
USE OF 16S RDNA SEQUENCING IN
CLINICAL MICROBIOLOGY
LABORATORIES
Bacterial identiﬁcation
Rapid and accurate identiﬁcation of bacterial
isolates is a fundamental task in clinical microbi-
ology, and provides insights into aetiologies of
infectious disease and appropriate antibiotic treat-
ment. Although conventional phenotypic meth-
ods are relatively inexpensive and allow
identiﬁcation of most commonly encountered
bacteria, certain groups of bacteria are difﬁcult
to identify, and special equipment and expertise
may be required, e.g. gas chromatography–mass
spectrometry for anaerobes. These methods also
fail in cases of rare bacteria or bacteria with
ambiguous proﬁles. Moreover, phenotypic meth-
ods rely on the availability of pure culture and are
dependent on subsequent growth characteristics
and biochemical proﬁling. Therefore, consider-
able time is required for slow-growing bacteria to
be identiﬁed. 16S rDNA sequencing represents a
universal technology that, theoretically, provides
solutions to these problems, yielding unambigu-
ous data, even for unusual and slow-growing
isolates, often within 48 h, which are reproducible
among laboratories.
Identiﬁcation of rare bacteria and bacteria with unusual
phenotypic proﬁles. 16S rDNA sequencing is partic-
ularly useful in identifying unusual bacteria that
are difﬁcult to identify by conventional methods,
providing genus identiﬁcation in >90% of cases,
and identiﬁcation of 65–83% of these at the species
level [7,8]. The MicroSeq 500 16S rDNA-based
identiﬁcation systemwas also able to identify 81%
of clinically signiﬁcant bacterial isolates with
ambiguous biochemical proﬁles and 89.2% of
unusual aerobic Gram-negative bacilli to the
species level [9,10].
In many situations, 16S rDNA sequencing is the
ultimate solution to identiﬁcation of aetiological
agents of infectious diseases caused by rarely
encountered bacteria [11–22]. This not only allows
correct identiﬁcation and selection of appropriate
treatment, but also contributes to a better under-
standing of the epidemiology and pathogenic role
of these bacteria, which has not been possible in
the past. For example, using 16S rDNA sequenc-
ing, cases of invasive Streptococcus iniae infections,
which had previously been reported only in
North America, have been recognized in Asia
[23–27].
Unlike phenotypic identiﬁcation, which can be
affected by the presence or absence of non-
housekeeping genes or by variability in expres-
sion of characters, 16S rDNA sequencing provides
accurate identiﬁcation of isolates with atypical
phenotypic characteristics. Using the technique, it
has been possible to identify thermotolerant
Campylobacter fetus strains as important causes of
bacteraemia in immunocompromised patients
[28]. Similar applications have also been shown
to have signiﬁcant impacts on the decision of
whether to prescribe antibiotic treatment [29–31]
and on the choice of speciﬁc antibiotic regimen
[32–34], which could lead to improved clinical
outcomes [10].
Mistakes in identifying rarely encountered or
phenotypically aberrant isolates are probably
quite common in clinical microbiology laborato-
ries. Sometimes, it is even difﬁcult to know
whether a bacterium has been incorrectly identi-
ﬁed. For example, using phenotypic methods,
Francisella tularensis subsp. novicida was consis-
tently misidentiﬁed twice, as Neisseria meningitidis
or Actinobacillus actinomycetemcomitans [35]. 16S
rDNA sequencing will continue to play a major
role in the identiﬁcation of rare bacteria and
bacteria with ambiguous characteristics in clinical
microbiology laboratories.
Identiﬁcation of slow-growing bacteria. 16S rDNA
sequencing and similar molecular identiﬁcation
methods have the additional advantage of
reducing the time required to identify slow-
growing bacteria such as mycobacteria, which
may take 6–8 weeks to grow in culture
sufﬁciently for phenotypic tests to be performed.
Even for rapidly growing mycobacteria, some
biochemical reactions may take up to 28 days to
complete. As for whole cell fatty acid analysis by
gas chromatography, this requires special equip-
ment and expertise that are often not available
in clinical microbiology laboratories. Therefore,
16S rDNA sequencing has been used for iden-
tiﬁcation of Mycobacterium species isolated from
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clinical specimens, making clinical diagnosis
more rapid and guiding prompt antibiotic treat-
ment [29,36]. Using this technique, we were able
to describe a novel clinical syndrome, acupunc-
ture mycobacteriosis, caused by relatively alco-
hol-resistant mycobacteria in patients receiving
acupuncture [37,38]. However, a limited number
of mycobacterial species could not be differen-
tiated from one another by 16S rDNA sequenc-
ing, e.g. Mycobacterium avium intracellulare and
M. paratuberculosis, M. chelonae and M. abscessus,
and members of the M. tuberculosis complex.
Therefore, other gene targets, sometimes supple-
mented by phenotypic results, have to be
used for differentiation of these species, e.g.
hsp65 and rpoB for those that grow rapidly, and
16S–23S rRNA internal transcribed spacer
or gyrB for the mycobacteria that grow slowly
[39–42].
Routine identiﬁcation. Several studies have been
conducted to compare the usefulness of 16S
rDNA sequencing with conventional or commer-
cial methods for the identiﬁcation of various
groups of medically important bacteria. In gen-
eral, 16S rDNA sequencing results in a higher
percentage of species identiﬁcation than conven-
tional or commercial methods. The success rate of
species identiﬁcation by 16S rDNA sequencing
ranged from 62% to 92%, depending on the
group of bacteria and the criteria used for species
deﬁnition [43–49]. However, there are ‘blind
spots’ within some major genera, in which 16S
rDNA sequences are not sufﬁciently discrimina-
tive for the identiﬁcation of certain species. In
these circumstances, alternative targets have to be
investigated. For example, groEL is a commonly
used essential gene other than 16S rDNA which is
useful for classiﬁcation and identiﬁcation of many
groups of bacteria, e.g. staphylococci and Burk-
holderia species [50,51]. In particular, it has been
shown to be useful in differentiating Burkholderia
pseudomallei from B. thailandensis, the 16S rDNA
sequences of which are indistinguishable [52,53].
Similarly, 16S rDNA sequencing has limited
discriminatory power for closely related Staphy-
lococcus species. Therefore, sequencing of groEL
and tuf has been proposed as being more reliable
for identiﬁcation of coagulase-negative staphylo-
cocci [47,54].
As simple conventional methods are often
available for commonly encountered bacteria,
16S rDNA sequencing for identiﬁcation of ‘rou-
tine’ bacterial strains is most useful in the context
of bacterial species that are often difﬁcult to
identify with phenotypic tests. This has led to a
better understanding of the epidemiology and
pathogenicity of these clinically ‘unidentiﬁable’
bacteria. One remarkable example is provided by
anaerobic Gram-positive rods, where conven-
tional methods are simply not reliable, even for
genus identiﬁcation; with the use of 16S rDNA
sequencing, many previously undescribed or
ignored anaerobic bacterial species were found
to contribute to cases of bacteraemia [55–59]. With
regard to streptococci, cases of b-haemolytic
Lanceﬁeld group G streptococcus bacteraemia
have been found to be almost exclusively caused
by S. dysgalactiae subsp. equisimilis using 16S
rDNA sequencing, although S. canis infections in
dog owners have been reported rarely [60,61]. In
another study, six cases of ‘S. milleri’ endocarditis
were attributed to S. anginosus, suggesting that
S. anginosus had the highest propensity to cause
infective endocarditis among the three species
of the ‘S. milleri group’ [62]. Using this ‘state-of-
the-art’ technique, it was also found that Haemo-
philus segnus is an important cause of non-H.
inﬂuenzae bacteraemia [19,63,64]. In addition, the
use of 16S rDNA sequencing for clinically ‘un-
identiﬁable’ bacteria could have clinical signiﬁ-
cance regarding the choice of antibiotic regimen
as well as the duration of treatment. For example,
we have previously reported a case of empyema
thoracis caused by Enterococcus cecorum that was
unidentiﬁed by conventional methods and three
commercial identiﬁcation systems. Unlike other
Enterococcus species, the organism is known to be
susceptible to cefotaxime and ceftriaxone. In this
case, the use of 16S rDNA sequencing not only
allowed continuation of cefotaxime as treatment
for the patient, who responded very well, but also
suggested that the bacterium’s cephalosporin
susceptibility could well be explained by its
unique phylogenetic position, it being the ances-
tor of other Enterococcus species and more closely
related to Streptococcus species [65]. In other
instances, 16S rDNA sequencing has been partic-
ularly useful in differentiating between Actino-
myces and non-Actinomyces anaerobic Gram-
positive bacilli, which is often difﬁcult in clinical
microbiology laboratories [66–68]. A deﬁnitive
diagnosis of actinomycosis is important, as
a prolonged course of appropriate antibiotic
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treatment (weeks to months) is indicated to
prevent relapse.
Novel bacterial genus and species discovery
During the process of bacterial identiﬁcation,
potential novel species will be encountered
when there is a signiﬁcant difference between
the phenotypic characteristics and ⁄ or 16S rDNA
sequences of the unknown bacterium and those
of the most closely related ones. As no single
test or gene sequence is ideal for the deﬁnition
of new species in all groups of bacteria, a
polyphasic approach is usually used when a
novel species is deﬁned. Depending on the
group of bacteria, this involves various combi-
nations of phenotypic characteristics, 16S rDNA
sequences, sequences of other housekeeping
genes, and DNA–DNA hybridization results. In
this section, we review the novel species dis-
covered from human specimens in the ﬁrst
7 years of the 21st century (2001–2007) in the
English literature.
According to the inclusion and exclusion crite-
ria used in the present article, 215 novel species,
29 of which belonged to novel genera, have been
discovered from human specimens in the past
7 years. Among these 215 novel species, 100 (15 of
novel genera) have been found in four or more
subjects (Table 1). Among these 100 novel species,
there were four (4%) aerobic Gram-positive cocci,
30 (30%) aerobic Gram-positive rods, three (3%)
aerobic Gram-negative cocci, 24 (24%) aerobic
Gram-negative rods, four (4%) anaerobic Gram-
positive cocci, ten (10%) anaerobic Gram-positive
rods, one (1%) anaerobic Gram-negative coccus,
22 (22%) anaerobic Gram-negative rods, and two
(2%) spirochaetes. The largest numbers of novel
species discovered and isolated from four or more
subjects were of the generaMycobacterium (n = 12)
and Nocardia (n = 6). The oral cavity ⁄dental-
related specimens (n = 19) and the gastrointesti-
nal tract specimens (n = 26) were the most
important for discovery and ⁄ or the most impor-
tant reservoirs of novel species. This is in line with
the huge diversity of potential novel bacterial
species in the human oral cavity and gastrointes-
tinal tract [69,70]. Among the 100 novel species,
S. sinensis, Laribacter hongkongensis, Clostridium
hathewayi and Borrelia spielmanii have been most
thoroughly characterized, with the reservoirs
and routes of transmission documented, and
S. sinensis, L. hongkongensis and C. hathewayi have
been found globally [71–89], although most No-
cardia and Mycobacterium species were probably
from the environment, and most anaerobes were
probably from the oral cavity and ⁄ or gastrointes-
tinal tract.
In our opinion, novel bacterial species recov-
ered from human specimens should be re-
ported, even if only one well-characterized
strain is available. Despite extensive investiga-
tions, a microbiological cause cannot be deter-
mined in approximately half of the patients
with infectious disease. For some clinical syn-
dromes, such as neutropenic fever, no microbi-
ological cause can be found in up to 80% of
patients who are believed to be suffering from
infective causes [90,91]. For some other syn-
dromes, e.g. acute gastroenteritis and commu-
nity-acquired pneumonia, the cause was
undetermined in c. 40% of patients [92,93]. Over
the years, tremendous efforts have been made
to determine the microorganisms associated
with these ‘unexplained infectious disease syn-
dromes’. The discovery of novel aetiological
agents responsible for ‘unexplained infectious
disease syndromes’ relies quite heavily on the
description of novel microbes. Although stan-
dard or unusual forms of known microbes are
sometimes considered to be novel causes of
‘unexplained infectious disease syndromes’
[94,95], most of the novel causes are indeed
previously undescribed microbes. There has
been much debate on the number of strains of
a particular bacterium required for description
of a novel bacterial species, but our experience
with the discovery and characterization of
L. hongkongensis and S. sinensis suggests that
any well-characterized strain of a novel bacterial
species recovered from human specimens
should be reported. Concerning L. hongkongensis,
when the bacterium was ﬁrst discovered, only
one strain was obtained [76]. The description of
the novel bacterium and the wide availability of
molecular techniques, sophisticated databases
and bioinformatics tools have made discovery
of additional strains from other countries and
rapid sharing of information possible [77]. This
has led to rapid conﬁrmation of its association
with gastroenteritis and the determination of
its reservoir [79]. In retrospect, if the ﬁrst strain
of L. hongkongensis had not been described,
the demonstration of its association with
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Table 1. Novel bacterial species discovered in four or more human subjects in the 21st century
Bacteria
Year of ﬁrst
publication References
Associated
diseases
Source of isolation
Reservoir ⁄
source of
infection
Human Non-human
Patients
Asymptomatic
individuals
Aerobic and facultative anaerobic Gram-positive cocci
Kytococcus schroeteri 2002 [159–162] Infective endocarditis,
pneumonia
Blood, BAL, prosthetic valve,
abscess pus
– – –
Streptococcus
oligofermentans
2003 [163] – – Dental plaque,
saliva
– –
S. pseudoporcinus 2006 [164] – Female genitourinary tract – – –
S. sinensis 2002 [71–75] Infective endocarditis Blood Saliva – Oral cavity
Aerobic and facultative anaerobic Gram-positive rods
Actinomyces
cardiffensis
2002 [165] Postmastoidectomy
brain and ear
abscesses, jaw abscess,
pericolic abscess,
sinusitis, pelvic
actinomycosis
Abscess pus, pleural ﬂuid, antral
washout, IUCD
– – –
A. funkei 2002 [166,167] – Blood, sternum, abdominal incision,
neck–face, thorax, pelvis, IUCD,
vagina ⁄penis, brain ⁄CSF, superﬁ-
cial soft tissue lesion
– – –
Biﬁdobacterium
scardovii
2002 [168] – Blood, urine, hip – – –
Brevibacterium
lutescens
2003 [169] Peritonitis Peritoneal ﬂuid, infected ear dis-
charge, peritoneal dialysate ﬂuid
– Peptone
preparation
–
Brevibacterium
paucivorans
2001 [170] – CSF, groin abscess, blood, ear dis-
charge, intravascular catheter,
wound, groin swab
– – –
Corynebacterium
aurimucosum
(= Corynebacterium
nigricans)
2002 [171–173] Meningitis, uterine
infection, UTI, vagini-
tis, placental infection,
vulval ulcer, female
urogenital tract infec-
tion
Cervix, bartholin gland, vagina,
CSF, endometrium, placenta, urine,
vulva, amniotic ﬂuid, blood, vaginal
swab, vaginal ulcer, vaginal–rectal
swab
– – –
Corynebacterium
freneyi
2001 [174,175] Bacteraemia Pus from toe, varicose ulcer, sub-
cutaneous abscess ﬁstula, blood
– – –
Corynebacterium
resistens
2005 [176] Bacteraemia, nosoco-
mial pneumonia,
cellulitis
Blood, bronchial aspirate, cellulitis
aspirate
– – –
Lactobacillus
coleohominis
2001 [177] – – Vagina, urine,
cervix
– –
Microbacterium
paraoxydans
2003 [178] Catheter-related bac-
teraemia
Blood, bronchial aspirate – Vegetable –
Mycobacterium
arupense
2006 [179] – Respiratory specimen, gastrointes-
tinal tract, various sterile sites, e.g.
tendon, lymph node, lung biopsy,
pleural ﬂuid, surgical tissue, urine
– – Possibly
environ
mental
M. bolletii 2006 [42] Chronic pneumonia Sputum, stomach aspirate – – –
M. canariasense 2004 [180] Catheter-related
bacteraemia
Blood – – –
M. colombiense 2006 [181] – Sputum, blood – – –
M. ﬂorentinum 2005 [182] Lymphadenopathy,
pneumonia
Sputum, stool, lymph node, gastric
aspirate, BAL
– – –
M. holsaticum 2002 [183,184] – Sputum, urine, gastric ﬂuid – Lymph node
of cattle with
evidence of bovine
tuberculosis
–
M. immunogenum 2001 [185–190] Disseminated cutane-
ous infection, keratitis,
catheter-related infec-
tion, septic arthritis,
chronic pneumonia,
pacemaker-related
sepsis, hypersensitiv-
ity pneumonitis,
chronic leg ulcer,
peritonitis
Skin, cornea, urine, intravenous
catheter site, joint ﬂuid, BAL, blood,
broviac site, leg biopsy, corneal
scraping, peritoneal ﬂuid of patients
receiving IPD
– Hospital environment,
metalworking ﬂuid,
environment, tap
water, water in
IPD machines
Probably
tap water
M. massiliense 2004 [191–193] Pneumonia, post-
intramuscular injec-
tion abscess, pace-
maker pocket
infection
Sputum, BAL, pus, tissue debris,
specimen from surgical debride-
ment, blood
– – –
Woo et al. Use of 16S rDNA gene sequence in clinical microbiology laboratories 913
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 908–934
Table 1. (continued)
Bacteria
Year of ﬁrst
publication References Associated diseases
Source of isolation
Reservoir ⁄
source of
infection
Human Non-human
Patients
Asymptomatic
individuals
M. monacense 2006 [194] Post-traumatic wound
infection
Biopsy, sputum, BAL – – Possibly
environmental
M. nebraskense 2004 [195,196] Respiratory infection Sputum, BAL – – –
M. palustre 2002 [184,197] Lymphadenitis Submandibular
lymph node biopsy
– Submandibular
lymph node of
pig, stream
water, lymph
node of cattle
with evidence
of bovine
tuberculosis
–
M. saskatchewanense 2004 [198] Pneumonia in bron-
chiectasis patients
Sputum, pleural ﬂuid,
respiratory sample
– – –
Nocardia africana 2001 [199,200] Pulmonary
nocardiosis
Sputum – Subcutaneous
nodule of cat
–
N. aobensis 2004 [201] – – – – –
N. arthritidis 2004 [202,203] Thigh abscess,
pulmonary
nocardiosis, keratitis
Sputum, thigh inﬂam-
matory swelling dis-
charge, cornea
– – –
N. asiatica 2004 [203–205] Pulmonary nocardio-
sis, skin infection,
keratitis, ocular
nocardiosis
Sputum, granuloma,
transtracheal aspirate,
cutaneous ulcer, cor-
nea, vitreous body
– – Possibly
environmental
N. ignorata 2001 [206–208] Pulmonary
nocardiosis
Sputum, BAL, blood,
tracheal aspirate
– Soil Probably soil
N. veterana 2001 [209–215] Pulmonary
nocardiosis, myce-
toma, bacteraemia,
peritonitis
BAL, subcutaneous
nodule biopsy, spu-
tum, open lung biopsy
tissue, ﬁne-needle
transthoracic biopsy
and aspirate, blood,
peritoneal ﬂuid
– – –
Olsenella profusaa 2001 [216–218] Periodontitis, acute
periradicular abscess
Subgingival plaque,
carious dental lesion,
root canal, pus
– – –
Weissella cibaria
(= Weissella kimchii)
2002 [219–225] – Gall Stool Ear of dog with
otitis, cheese whey,
sugar cane, canary
liver, chili bo, tapai,
wheat sourdough,
blood sausage,
faecal swab of
healthy dog,
plaa-som (fermented
ﬁsh product from
Thailand),
fermented kimchii,
whole crop paddy
rice silage
–
Aerobic and facultative anaerobic Gram-negative cocci
Achromobacter
insolitus
2003 [226] – Urine, wound – Laboratory sink –
Achromobacter
spanius
2003 [226] – Blood – – –
Kerstersia gyioruma 2003 [227] – Stool, leg and ankle
wounds, sputum
– – –
Aerobic and facultative anaerobic Gram-negative rods
Acinetobacter parvus 2003 [228] Catheter-related
bacteraemia
Ear, eye, forehead,
skin, blood
– Ear of dog with
refractory otitis
media
–
Acinetobacter
schindleri
2001 [229,230] Cystitis, bacteraemia Urine, vagina, throat,
ear, nasal swab, con-
junctiva, skin, pleural
effusion, liquor,
blood, central catheter
– – –
Acinetobacter ursingii2001 [229–231] Infective endocarditis,
bacteraemia, UTI,
postneurosurgical
meningitis,
cholangitis, cervical
adenopathy
Blood, intravenous
line, pus, ulcer, eye,
wound, urine, hairy
skin, toe, abscess, cen-
tral catheter, ganglion
biopsy, CSF
– – –
Advenella incenataa 2005 [232] – Sputum, blood – Horse blood –
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gastroenteritis would have been hampered.
Therefore, in the context of pathogenic mi-
crobes, we think that even one strain of a novel
species should be described, so that global,
concerted efforts can be made to identify more
cases associated with that pathogen.
Table 1. (continued)
Bacteria
Year of ﬁrst
publication References Associated diseases
Source of isolation
Reservoir ⁄
source of
infection
Human Non-human
Patients
Asymptomatic
individuals
Averyella
dalhousiensisa
2005 [233] Catheter-related
bacteraemia,
cellulitis, wound
infection
Wound, stool, blood,
intestinal ﬂuid
– – –
Burkholderia
ambifaria
2001 [234,235] Keratitis Sputum and respira-
tory tract of CF pa-
tients, corneal culture
– Biocontrol strains;
corn roots; corn,
pea, snap bean
and sedge
rhizosphere; forest
soil, leaves of
Sesbania exaltata,
commercial soil
–
B. fungorum 2001 [236,237] Septic arthritis Vaginal secretion of
pregnant woman,
CSF, blood
– White-rot fungus
Phanerochaete
chrysosporium,
mouse nose,
haemoglobin
solution
–
Campylobacter
hominis
2001 [88,238,239] Bacteraemia Blood Stool – Gastrointestinal
tract
Cardiobacterium
valvarum
2004 [240–244] Infective
endocarditis,
prosthetic valve
endocarditis
Blood, noma lesion – – Probably oral
cavity
Cupriavidus
respiraculi
(= Wautersia
respiraculi
= Ralstonia
respiraculi)
2003 [245–247] – Sputum and respira-
tory tract of CF pa-
tients
– – –
Enterobacter ludwigii 2005 [248] Nosocomial UTI Urine, trachea, fat tis-
sue of left thigh, ve-
nous line, sputum,
blood, stool, BAL,
biopsy, throat, skin,
swab
– – –
Escherichia albertii 2003 [249] Diarrhoea Stool – – Probably
gastrointestinal
tract
Granulibacter
bethesdensisa
2006 [250,251] Lymphadenitis in
CGD patients
Lymph node – – –
Haematobacter
massiliensisa
(= Rhodobacter
massiliensis)
2003 [252,253] Bacteraemia, wound
infection
Nose, blood, wound – – –
Halomonas
phocaeensis
2007 [254] Fresh frozen plasma
transfusion-associated
bacteraemia ⁄pseudo-
bacteraemia
Blood – – Probably
environmental,
e.g. water
Helicobacter
winghamensis
2001 [255,256] – Stool of patients with
gastroenteritis
– Stool of gerbils Probably
gastrointestinal
tract
Inquilinus limosusa 2002 [257–261] Acute respiratory
exacerbation and pro-
gressive loss of pul-
monary function in CF
patients?
Respiratory secretion
and sputum of CF
patients
– Roots of grass Possibly
environmental
Laribacter
hongkongensisa
2001 [76–84,
262–265]
Bacteraemia, empy-
ema thoracis,
community-acquired
gastroenteritis, travel-
lers’ diarrhoea
Blood, empyema pus,
stool
– Freshwater ﬁsh,
drinking water
reservoir
Freshwater ﬁsh
Neisseria bacilliformis2006 [266] Wound infection,
bronchitis, lung ab-
scess
Ear, blood, oral ﬁstula,
submandibular
wound, sputum, lung
abscess
– – Possibly
oral cavity
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Table 1. (continued)
Bacteria
Year of ﬁrst
publication References Associated diseases
Source of isolation
Reservoir ⁄
source of
infection
Human Non-human
Patients
Asymptomatic
individuals
Paracoccus yeei 2003 [267] CAPD peritonitis, wound infection,
biliary tract infection, bacteraemia
Abdominal dialysate, wound, bile,
CSF, blood
– – –
Pseudomonas mosselii2002 [268,269] – Tracheal aspirate, bronchial aspi-
rate, blood, venous catheter, stool,
drainage liquid
– Mineral
water
–
P. otitidis 2006 [270] Acute otitis externa, acute otitis
media, chronic suppurative otitis
media
Ear of patients with acute otitis
externa, acute otitis media, chronic
suppurative otitis media
– – –
Ralstonia taiwanensis2001 [271] – Sputum of CF patients – Root nodule
of Mimosa
species
–
Wautersiella falseniia 2006 [272] – Blood, wound, pus, respiratory
tract, ear discharge, vaginal swab,
pleural ﬂuid, oral cavity
– – –
Anaerobic Gram-positive cocci
Anaerococcus
murdochii
2007 [273] Infected foot ulcer,
infected sternal wound, soft tissue
neck infection, post-traumatic
thumb abscess
Wound, abscess – – –
Peptoniphilus
gorbachii
2007 [273] Infected dry gangrene, cellulitis,
infected diabetic foot ulcer
Wound – – –
Peptoniphilus olsenii 2007 [273] Osteomyelitis, infected dry gan-
grene, infected diabetic foot ulcer,
toe infection
Bone, wound – – –
Peptostreptococcus
stomatis
2006 [274,275] Dento-alveolar abscess, endodontic
infection, pericoronal infection,
bacteraemia
Specimen from infected structure of
oral cavity, oropharyngeal speci-
men, appendix, stool, blood
– – Possibly oral
cavity and
gastrointestinal
tract
Anaerobic Gram-positive rods
Alloscardovia
omnicolensa
2007 [276] – Urine, blood, urethra, oral cavity,
tonsil, abscesses of lung and aortic
valve
– – –
Anaerostipes caccaea 2002 [277,278] – – Stool – Probably
gastrointestinal
tract
Catabacter
hongkongensisa
2007 [59] Bacteraemia Blood – – Probably
gastrointestinal
tract
Clostridium bolteae 2003 [279–281] Bacteraemia, intra-abdominal ab-
scess, necrotizing fasciitis, pelvic
abscess, wound infection
Blood, intra-abdominal abscess, ab-
scess, wound
Stool – Probably
gastrointestinal
tract
C. hiranonis 2001 [282,283] – – Stool – Probably
gastrointestinal
tract
Eggerthella
hongkongensis
2004 [55] Perianal abscess, infected rectal tu-
mour, liver abscess, appendicitis
Blood – – Probably
gastrointestinal
tract
Lactobacillus
ultunensis
2005 [284–286] – Carious dentine Gastric
mucosa
biopsy
Stool
of pigs
–
Roseburia intestinalis 2002 [287] – – Stool – Probably
gastrointestinal
tract
Shuttleworthia
satellesa
2002 [288] Periodontitis Periodontal pocket, subgingival
plaque
– – Probably oral
cavity
Varibaculum
cambriensisa
2003 [289] Facial abscess, otogenic cerebral
abscess
Abscess, IUCD – – Possibly oral
cavity
Anaerobic Gram-negative cocci
Veillonella
montpellierensis
2004 [290,291] Infective endocarditis Gastric ﬂuid, amniotic ﬂuid, blood – – –
Anaerobic Gram-negative rods
Alistipes onderdonkii 2006 [292] Intra-abdominal infection Appendix, abdominal abscess,
stool, urine
Stool – Probably
gastrointestinal
tract
Alistipes shahii 2006 [292] Intra-abdominal infection Intra-abdominal
ﬂuid and appendix
Stool – Probably
gastrointestinal
tract
Bacteroides
intestinalis
2006 [293] – – Stool – Probably
gastrointestinal
tract
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Table 1. (continued)
Bacteria
Year of ﬁrst
publication References Associated diseases
Source of isolation
Reservoir ⁄
source of
infection
Human Non-human
Patients
Asymptomatic
individuals
Bacteroides plebeius 2005 [294] – – Stool – Probably
gastrointestinal
tract
Cetobacterium
somerae
2003 [295] – – Stool – Probably
gastrointestinal
tract
Clostridium
hathewayib
2001 [85–88] Bacteraemic acute
cholecystitis and liver
abscess, bacteraemic
acute gangrenous
appendicitis, bactera-
emia
Blood, liver abscess Stool – Gastrointestina
tract
Desulfomicrobium
orale
2001 [296] Periodontitis Subgingival plaque – – Probably oral
cavity
Dialister invisus 2003 [128,
297–299]
Endodontic and peri-
odontal infections,
UTI, acute periradicu-
lar abscess, acute per-
iradicular periodonti-
tis, acute apical
abscess
Dental root canal,
deep periodontal
pocket, urine of renal
transplant recipients,
abscess pus, abscess
aspirate
– – –
Dialister
micraerophilus
2005 [300,301] Anal, buttock, breast,
perinephric abscess,
bacteraemia, wound
infection
Amniotic ﬂuid, blood,
pilonidal cyst, abscess
pus, bone, bartholin
gland, wound, phleg-
mon, skin and soft
tissues, vagina
– – –
Dialister
propionicifaciens
2005 [300] Groin abscess, wound
infection
Pressure ulcer, semen,
abscess pus, wound
– – –
Dysgonomonasmossii 2002 [302,303] – Biliary drainage,
abdominal drain,
intestinal juice
– – –
Leptotrichia amnionii 2002 [304–307] Septic arthritis, cho-
rioamnionitis, renal
abscess
Amniotic ﬂuid, joint
ﬂuid, blood, renal ab-
scess pus
– – Possibly female
genital tract
Parabacteroides gold-
steinii (= Bacteroides
goldsteinii)
2005 [308,309] Peritonitis, appendici-
tis, intra-abdominal
abscess
Peritoneal ﬂuid,
appendix tissue, intra-
abdominal abscess
– – Probably
gastrointestinal
tract
Porphyromonas
somerae
2005 [310] Chronic skin and soft
tissue infections, oste-
omyelitis
Skin and soft tissues,
bone
– – –
Porphyromonas
uenonis
2004 [311] Appendicitis, perito-
nitis, pilonidal ab-
scess, infected sacral
decubitus ulcer
Stool – – Probably
gastrointestinal
tract
Prevotella baroniae 2005 [312] Endodontic and peri-
odontal infections,
dentoalveolar abscess
Oral cavity Dental
plaque
– –
Prevotella bergensis 2006 [313] Skin and soft tissue
abscesses, wound
infection
Wound, decubitus
ulcer
– – –
Prevotella copri 2007 [314] – – Stool – Probably
gastrointestinal
tract
Prevotella marshii 2005 [312] Endodontic and peri-
odontal infections
Oral cavity Subgingival
dental
plaque
– –
Prevotellamultiformis 2005 [315] Chronic periodontitis Subgingival plaque – – –
Prevotella
multisaccharivorax
2005 [316] Chronic periodontitis Subgingival plaque – – –
Sneathia
sanguinegensa
2001 [317,318] Postpartum bactera-
emia
Blood, amniotic ﬂuid – – Probably female
genital tract
Spirochetes
Borrelia spielmanii
(= Borrelia spielmani)
2004 [89] Lyme disease Erythema migrans le-
sion
– Ticks Garden dormice
Treponema parvum 2001 [319] Periodontitis, acute
necrotizing ulcerative
gingivitis, acute and
chronic apical peri-
odontitis
Subgingival plaque,
acute necrotizing
ulcerative gingivitis
lesion, root canal
– – –
aAlso a novel genus.
bThe isolates discovered by Steer et al. were Gram-positive, but those found in the subsequent studies were Gram-negative.
BAL, bronchoalveolar lavage; IUCD, intrauterine contraceptive device; CSF, cerebrospinal ﬂuid; UTI, urinary tract infection; CGD, chronic granulomatous disease; CF, cystic
ﬁbrosis; CAPD, continuous ambulatory peritoneal dialysis; IPD, intermittent peritoneal dialysis.
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Detection of uncultivable bacteria and diagnosis
of culture-negative infections
Bacterial culture had been the most important
technique for diagnosing bacterial infections since
the ﬁrst days of microbiology. Indeed, Koch’s
original postulates explicitly required that the
pathogen be grown in a pure culture. This speciﬁc
requirement has since been updated, and the
clinical importance of ‘uncultivable’ bacteria, e.g.
Treponema pallidum, is now well recognized.
Nonetheless, given the central role of bacterial
culture in most clinical laboratories, the diagnosis
of culture-negative infections and those caused by
uncultivable bacteria remains a somewhat ardu-
ous task. Direct microscopy and immunology-
based assays have been the culture-independent
methods traditionally used. The sensitivities and
speciﬁcities of these methods can vary greatly,
depending on the implementation and the organ-
isms concerned. Direct microscopic examination
demands a signiﬁcant microbial presence in the
specimen for positive identiﬁcation, and serolog-
ical tests suffer from cross-reactivities and may be
affected by a patient’s immunocompromised
status. The introduction of molecular diagnostics
signiﬁcantly enhanced the ability to diagnose
culture-negative infections. Among the various
molecular assays available, 16S rDNA sequencing
stands out as a useful technique for detecting
uncultivable bacteria. The universal presence and
sequence conservation of the gene allows broad-
range PCR primers to be readily designed. This
characteristic is of great importance, as it would
be impractical to perform multiple speciﬁc assays
to rule out individual bacteria associated with the
disease.
An important use of 16S rDNA sequencing is
the identiﬁcation of clinical syndromes caused by
uncultivable bacteria. These relate to infections
caused by bacteria that could not be cultured
reliably by known methods at the time of discov-
ery. For example, Whipple’s disease was known
only as a systemic disorder of unknown aetiology
when ﬁrst described in 1907. Since then, gradual
progress towards better diagnosis and treatment
of the disease has been made, although the classic
method of periodic acid–Schiff staining for diag-
nosis lacks both sensitivity and speciﬁcity when
used alone. The ﬁrst breakthrough in the under-
standing of Whipple’s disease arrived with the
identiﬁcation of Tropheryma whippeli as the caus-
ative agent. This was accomplished by the PCR
ampliﬁcation and sequencing of its 16S rDNA
gene [96,97]. The 16S rDNA sequence allowed the
phylogenetic position of T. whippeli to be deﬁned
immediately, and enabled the later development
of molecular diagnostic tests [97–100]. The deﬁn-
itive identiﬁcation of the aetiological agent greatly
accelerated research into the pathophysiology of
the disease. In 2003, the genome sequences of two
T. whipplei strains were completed [101,102],
marking another milestone in medical history.
Similar successes were seen in the context of
bacillary angiomatosis (caused by Bartonella hense-
lae and Bartonella quintana) [103,104] and human
ehrlichiosis (caused by bacteria of the genera
Ehrlichia and Anaplasma) [105–107].
16S rDNA sequencing has also been used for
diagnosing culture-negative infections, the best
example being culture-negative endocarditis. Up
to one-third of all cases of infective endocarditis
are culture-negative [108], and diagnosis has
relied mainly upon clinical and ultrasonographic
ﬁndings. Goldenberger et al. reported one of the
earliest situations in which 16S rDNA PCR ampli-
ﬁcation and sequencing were performed on DNA
extracted from infected valves [109]. Many sub-
sequent studies conﬁrmed the usefulness of the
method [110–119]. In general, the sensitivity was
found to be comparable to that of serological
testing and histopathological examination. An
interesting and important result of these studies
is the recognition that many culture-negative
cases were caused by cultivable Gram-positive
bacteria, but the blood culture results might have
been negative due to previous antibiotic usage.
Other factors that may contribute to the false-
negative blood culture results include inadequate
microbiological techniques, e.g. use of an insufﬁ-
cient volume of blood, or infection by a fastidious
organism [120].
Diagnosis of other culture-negative infec-
tions, including meningitis [121–125], brain ab-
scess [126], keratitis [127], urinary tract infections
[128], empyema [129,130], septic arthritis [131,132]
and septicaemia [120,133,134], also beneﬁts from
the use of 16S rDNA sequencing. The encourag-
ing results from these studies reinforced the idea
that 16S rDNA sequencing is broadly applicable
as a diagnostic technique in the context of clinical
microbiology. Future developments should in-
volve further optimization of universal primer
sets and attempts to discriminate between
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positive results and contamination or true
pathogens. Recent progress in these areas has
been made through the use of a broad-range real-
time PCR design [124,135,136]. With continued
improvements in performance and cost proﬁle,
16S rDNA sequencing is expected to play an
increasingly signiﬁcant role in the diagnosis of
culture-negative bacterial infections.
Automation of 16S rDNA sequencing
One of the greatest hurdles in putting 16S rDNA
sequencing into routine use in clinical micro-
biology laboratories is automation of the tech-
nology. At present, complete automation of 16S
rDNA sequencing, i.e. input of the bacterial
isolate ⁄ clinical sample for identiﬁcation or its
extracted DNA into a machine that will generate
the result of the identity of the isolate, is
impossible. Most of the steps, including DNA
extraction, PCR ampliﬁcation, puriﬁcation of
PCR products, DNA sequencing and sequence
editing, have to be performed manually,
although user-friendly commercial kits for some
of these steps are available. With the advances in
high-throughput technologies, these steps may
be incorporated into a robotic system, making
complete automation of 16S rDNA sequencing
possible in the future.
At present, the only steps that can be auto-
mated are the input of the ﬁnalized 16S rDNA
sequence concerned into one of the software
packages that contains a database with 16S rDNA
sequences of selected bacterial species and the
output of the result of the identity of the isolate.
The most well known of these software packages
include Ribosomal Database Project (RDP-II)
[137–141], MicroSeq [9,48,142,143], Ribosomal
Differentiation of Medical Microorganisms (RI-
DOM) [144–146] and the SmartGene Intergrated
Database Network System (SmartGene IDNS)
[147] (Table 2). The databases of RDP-II and
SmartGene IDNS contain sequences downloaded
from GenBank, whereas all sequences in the
databases of RIDOM and MicroSeq were obtained
by sequencing the 16S rDNA genes of bacterial
strains of culture collections.
The major studies that have evaluated the
usefulness of the various software packages for
different groups of bacteria are summarized in
Table 3. However, it is not possible to compare
accuracy among the different studies, because T
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Table 3. Studies on the usefulness of commonly used software pachages for bacterial identiﬁcation using 16S rDNA
sequencing
References Bacterial isolates tested Methods for determination of real identity of the isolates Accuracy of software
Tang et al. [10] 65 unusual aerobic Gram-negative
bacilli from clinical specimens
Conventional phenotypic methods MicroSeq 500: 89.2% (72% of 25 fermenters
and 100% of 40 non-fermenters; 97.2% to
genus level)
Tang et al. [143] 52 coryneform Gram-positive bacilli
(42 Corynebacterium species and 10
Corynebacterium-related species)
from clinical specimens
Conventional phenotypic methodsa MicroSeq 500: 66.7%a (100% to genus level)
Patel et al. [142] 113 Mycobacterium clinical isolates
(18 different species)
Combination of phenotypic methods, 16S rDNA sequenc-
ing using the MicroSeq database, and other methods, e.g.
standard biochemical assays, hsp65 gene sequencing,
AccuProbe rRNA hybridization, HPLC of mycolic acids.
Identiﬁcations were counted as correct if two methods
provided the same answer
MicroSeq 500 (version 1.36): 92.8%b
Turenne et al.
[321]
79 non-tuberculous mycobacterial
isolates (ATCC type strains)
Not described, but all were ATCC strains BLAST (GenBank and EMBL databases,
dated 30 March 2001): 38%c
RDP-II (dated 30 March 2001): 41%c
RIDOM (dated 8 March 2001): 100%c
Cloud et al. [148] 119 Mycobacterium isolates (94 clin-
ical isolates and 25 ATCC strains)
Combination of conventional phenotypic methods, 16S
rDNA sequencing using MicroSeq and RIDOM databases,
and additional tests on problematic isolates
MicroSeq 500 (version 1.36) in conjunction
with RIDOM database: 96.6%d (100% of 25
ATCC strains and 95.7% of 94 clinical iso-
lates)
Mellmann et al.
[149]
81 Nocardia clinical isolates Combination of conventional phenotypic methods, 16S
rDNA sequencing using MicroSeq and RIDOM databases
RIDOM (version 1.1): 100%e
MicroSeq 500 (version 1.4.3, library version
500-0125): 44.4%e
Woo et al. [9] 37 (15 aerobic or facultative anaer-
obic Gram-positive; 11 aerobic, mi-
cro-aerophilic or facultative
anaerobic Gram-negative, seven
anaerobic; three mycobacterial; and
one mycoplasma) clinical isolates
with ambiguous biochemical pro-
ﬁles
Combination of phenotypic methods and full 16S rDNA
sequencing
MicroSeq 500 (version 1.0): 81.1% (86.5% to
genus level)
Hall et al. [43] 387 Mycobacterium isolates (59
ATCC strains and 328 clinical iso-
lates)
Combination of conventional phenotypic methods, HPLC,
PCR restriction analysis of 65-kDa heat shock protein
region, 16S rDNA sequencing using MicroSeq 500 data-
base
MicroSeq 500 (version 1.4.2): 68% (98.3% of
59 ATCC strains and 62.5% of 328 clinical
isolates)
Cloud et al. [150] 94 Nocardia clinical isolates (ten
separate species)
Combination of conventional phenotypic methods, 16S
rDNA sequencing using expanded MicroSeq 500 data-
base, restriction endonuclease assay for portions of 16S
rDNA and hsp65 genes, sequencing of a 999-bp fragment of
the 16S rDNA gene
Expanded MicroSeq 500 (version 1.4.3,
library version 500-0125)f: 82%
Becker et al. [151] 55 clinical Staphylococcus isolates Combination of phenotypic methods, 16S rDNA sequenc-
ing using RIDOM and NCBI databases and additional tests
(chemotaxonomy and riboprinting) on isolates with
ambiguous or below the-threshold RIDOM results
RIDOM (version 1.2): 90.9%g
GenBank (dated 12 January 2004): 65.5%g
Lau et al. [48] 20 anaerobic Gram-positive bacilli
isolated from blood cultures
Preliminary phenotypic methods and full 16S rDNA
sequencing
MicroSeq 500 (version 1.0): 65% (80% to
genus level)
Patel et al. [322] 99 aerobic actinomycetes (28 refer-
ence strains and 71 clinical isolates,
including members of the genera
Streptomyces, Gordonia, and Tsukam-
urella, and ten taxa of Nocardia)
Phenotyping, PRA, drug susceptibility testing Microseq 500: 70.3%h
BLAST (GenBank): 70.3%i
Fontana et al.
[152]
83 (25 Gram-positive and 58 Gram-
negative) clinical isolates not iden-
tiﬁable by conventional systems
Not mentioned Not determined
Simmon et al.
[147]
300 (158 Gram-positive and 142
Gram-negative) clinical isolates
Combination of conventional phenotypic methods and 16S
rDNA sequencing using SmartGene IDNS and MicroSeq
500 databases
SmartGene IDNS (version 3.2.3r8): 87%
(98% to genus level)j MicroSeq 500 (version
1.4.3): 74% (90% to genus level)j
hsp65, heat shock protein 65; ATCC, American Type Culture Collection; BLAST, Basic Local Alignment Search Tool; EMBL, European Molecular Biology Laboratory; JCM,
Japan Collection of Microorganisms; PRA, PCR-restriction endonuclease analysis.
aFour of the 52 isolates not identiﬁed by conventional phenotypic methods were not included.
bTwo of the 113 isolates not identiﬁed by phenotypic methods were not included.
cIdentiﬁcation was considered correct if it was the best matched species, although not a perfect match. Over 1400 bp of the 16S gene was aligned in BLAST and RDP-II,
whereas Escherchia coli bp 54–510 was used in RIDOM.
dSequences resulting in distance score of <0.8%.
eSimilarity ‡99.12% reported by either RIDOM or MicroSeq.
fAn expanded portion of the database was developed from partial 5¢ 16S rDNA sequences derived from 28 reference strains (from ATCC and JCM); samples with 99–100%
similarity to a species in the expanded MicroSeq 500 library were assigned that species designation, provided that the colony morphology and growth characteristics were
consistent.
gPartial 16S rDNA fragment (corresponding to E. coli positions 54–510); classiﬁcation is based on percentage similarity ‡98.5 to the 16S rDNA sequence of the type and
reference strain.
hEight of the 99 isolates not identiﬁed by phenotypic methods were not included. Eighty per cent of 30 Actinomadura, Gordona, Rhodococcus, Streptomyces and Tsukamurella
species, and 65.6% of 61 Nocardia species.
iEight of the 99 isolates not identiﬁed by phenotypic methods were not included. Fifty per cent of 30 Actinomadura, Gordona, Rhodococcus, Streptomyces and Tsukamurella species,
and 80.3% of 61 Nocardia species.
jGenus-level and species-level identiﬁcations were assigned using the following criteria: ‡99% identity to a reference entry identiﬁed a bacterium to the species level, 97.0–
98.9% identity identiﬁed a bacterium to the genus level, and <97% identity to any sequence was considered to be unable to provide a deﬁnite identiﬁcation.
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bacterial isolates from different sources (reference
strains vs. clinical strains, identiﬁable strains vs.
unidentiﬁed strains), different reference stan-
dards and different criteria for ‘correct’ identiﬁ-
cation were used in the different studies. In some
studies, the identities of the isolates were deter-
mined by a combination of phenotypic and
genotypic methods [43,142,147–151]. In others,
such as a recent one on a heterogeneous group of
clinical isolates, no reference standard was men-
tioned, except whether the isolates were ‘identi-
ﬁed’ by MicroSeq [152]. As there are intrinsic
problems with MicroSeq, e.g. inclusion of bacte-
rial species with 16S rDNA sequences with
minimal differences from those of some other
species, it would be difﬁcult for readers to assess
the usefulness of MicroSeq from this study. As the
intrinsic problems of the software packages may
not be fully addressed in the publications, some of
the reported accuracies of the software packages
described may be overestimated.
USEFULNESS AND LIMITATIONS OF
USING 16S RDNA SEQUENCING IN
CLINICAL MICROBIOLOGY
LABORATORIES
Although 16S rDNA sequencing is being used
increasingly for bacterial identiﬁcation in clinical
microbiology laboratories, there are no widely
accepted guidelines for using the technique or for
the interpretation of sequence data. Given the
limitations of the technique for some taxa, the
ever-expanding sequence databases and taxo-
nomic complexity, and the inaccuracies in some
databases, some recommendations have been
suggested for the use of 16S rDNA sequencing
for bacterial identiﬁcation [7,153]. For indications
for the use of 16S rDNA sequencing, the strains
most often chosen are those that cannot be
accurately identiﬁed with phenotypic tests in
clinical microbiology laboratories. However, as
certain groups of bacteria are known to present
difﬁculties in identiﬁcation by 16S rDNA sequen-
cing, these bacteria should be excluded, and other
housekeeping gene targets, e.g. rpoB, if available,
are required [39–42,47,50–54,153]. Regarding the
interpretation of sequence data, this involves
requirements concerning the length and quality
of sequences, the choice of appropriate programs
for analysis, and the ﬁnal species assignment
based on similarity search results. Although a
minimum of 500–525 bp that includes the more
variable 5¢-region may be adequate for identiﬁca-
tion of some groups of bacteria, Drancourt et al.,
according to their several recommendations con-
cerning the criteria for 16S rDNA sequencing as a
reference method for bacterial identiﬁcation, pro-
posed that full 16S rDNA sequences with <1%
ambiguities should be used [7]. The comparison
should be made using at least 1500 positions in all
sequences, of the same length, included in the
similarity search, and an ungapped program
should be used. In a recent review by Janda and
Abbott, the use of full 16S rDNA sequences,
whenever possible, and in particular for groups
such as Campylobacter species [153], was con-
ﬁrmed as a viable technique.
The major difﬁculties and controversies in the
interpretation of sequence data concern the
assignment of bacterial species according to sim-
ilarity search results, as no threshold values are
available, as in the case of DNA–DNA hybridiza-
tion [154]. Although a 97% similarity level has
been proposed for bacterial speciation using 16S
rDNA sequences [155], a >0.5% difference may be
indicative of a new species [156]. In fact, as
different bacterial species are likely to evolve at
different rates, it is impossible to determine a
universal cut-off for bacterial genus and species
delineation. Although, in the study by Drancourt
et al., >99% and >97% sequence similarities were
used as the cut-offs for species and genus iden-
tiﬁcation, respectively, the authors indicated that
these sharp values were set mainly for practical
purposes, for interpretation of their large
sequence dataset, and it may be necessary to use
different cut-off values, depending on the bacte-
rial genus under investigation [7]. On the other
hand, Janda and Abbott, in their recommended
guidelines, suggested that a minimum of >99%,
and ideally >99.5%, sequence similarity be used
as the criteria for species identiﬁcation [153]. They
also proposed that for matches with distance
scores <0.5% to the next closest species, other
properties, e.g. phenotype, should be considered
in ﬁnal species identiﬁcation. However, using
these criteria, it is difﬁcult to determine the
species identity with sequences that have very
similar distances to the closest and next closest
matches, especially those within 0.5–1%.
Although different studies have identiﬁed groups
of bacteria for which 16S rDNA sequences are not
sufﬁciently discriminative and for which other
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gene targets have to be used, very few studies
have addressed and attempted to solve this
problem in a systematic way.
The use of 16S rDNA sequencing for bacterial
identiﬁcation depends on signiﬁcant interspecies
differences and small intraspecies differences in
16S rDNA sequences. Therefore, one of the major
limitations is that when two different bacterial
species share almost the same 16S rDNA
sequence, this technique would not be useful for
distinguishing between them. In our experience,
clinical microbiologists and technicians with lim-
ited experience in 16S rDNA sequencing often
ﬁnd interpretation of 16S rDNA similarity search
results difﬁcult. As a result of the large number of
unvalidated 16S rDNA sequences in GenBank, it
is not a straightforward task for inexperienced
users to decide whether the ‘ﬁrst hit’ or ‘closest
match’ represents the actual identity of a bacterial
isolate.
Regarding the software packages described
above, the usefulness is further limited by the
choice of bacterial species in the database. If a
bacterial species is not included in the database, it
would never be given as the identity of an isolate,
and if the database also includes bacterial species
with minimal differences in their 16S rDNA
sequences and which, therefore, cannot be iden-
tiﬁed conﬁdently by 16S rDNA sequencing, this
may also give rise to incorrect identiﬁcation.
In view of these limitations, we initiated a
systematic evaluation of the potential usefulness
of full and 527-bp 16S rDNA sequencing and
the existing MicroSeq databases for identiﬁca-
tion of medically important bacteria 2 years ago.
The species of medically important bacteria
included in this analysis comprise all species
of medically important bacteria listed in the
Manual of Clinical Microbiology [157]. The most
representative 16S rDNA sequence for each
species was chosen from the GenBank database.
The percentage differences of the 16S rDNA
sequences among the different species in the
same group ⁄genus were determined by pairwise
alignment.
The study ﬁrst involved medically important
anaerobic bacteria, and the results were published
in 2007 [158]. Each medically important bacterial
species is classiﬁed as one of the following: (i) the
bacterium can be conﬁdently identiﬁed by 16S
rDNA sequencing ( in Table 4 and Supplemen-
tary Tables 2–4 of reference [158]), meaning that
there is a >3% difference between the 16S rDNA
sequence of the species and those of other
medically important bacteria; (ii) the bacterium
cannot be conﬁdently identiﬁed by 16S rDNA
sequencing (· in Table 4 and Supplementary
Tables 2–4 of reference [158]), meaning that there
is a <2% difference between the 16S rDNA
sequence of the species and that of a closely
related medically important bacterium; and (iii)
the bacterium can only be doubtfully identiﬁed by
16S rDNA sequencing (? in Table 4 and Supple-
mentary Tables 2–4 of reference [158]), meaning
that there is a 2–3% difference between the 16S
Table 4. An example of guidelines for interpretation of
usefulness of full 16S rDNA sequencing and MicroSeq full
16S rDNA bacterial identiﬁcation system database for
identiﬁcation of medically important Actinomyces species
(adapted from Supplementary Table 2 of reference [158]
with permission)
Actinomyces
species
Usefulness
for species
identiﬁcation
Medically
important
bacteria with
similar (<3%
difference)
full 16S rDNA
gene sequences
Usefulness of
existing MicroSeq
full 16S rDNA
bacterial
identiﬁcation
system database
A. bovis ? A. urogenitalis ?c
A. bowdeni ? A. viscosus ·a
A. canis  ·a
A. catuli  ·a
A. denticolens  ·a
A. europaeu  ·a
A. funkei ? A. hyovaginalis ·a
A. georgiae ? A. meyeri ·a
A. gerencseriae  ·a
A. graevenitzii ·a
A. hordeovulneris  ·a
A. howellii  
A. hyovaginalis ? A. funkei ·a
A. israelii  ·a
A. meyeri ? A. georgiae,
A. odontolyticus,
A. turicensis
?c
A. naeslundii · A. viscosus ·a
A. neuii  
A. odontolyticus · A. meyeri,
A. turicensis
·a
A. radicidentis  ·a
A. radingae  
A. slackii  
A. turicensis · A. meyeri,
A. odontolyticus
·a
A. urogenitalis ? A. bovis ·a
A. viscosus · A. bowdenii,
A. naeslundii
·b
, >3% difference between the 16S rDNA gene sequence of the species and those of
other medically important bacteria; ?, 2–3% difference between the 16S rDNA gene
sequence of the species and that of a closely related medically important bacterium;
·, <2% difference between the 16S rDNA gene sequence of the species and that of a
closely related medically important bacterium.
aThe species is not included in the existing MicroSeq full 16S rDNA bacterial
identiﬁcation system database.
bAlthough the species is included in the existing MicroSeq full 16S rDNA bacterial
identiﬁcation system database, the high 16S rDNA gene sequence similarity (>98%
nucleotide identity) between the species and a closely related species does not allow
them to be distinguished conﬁdently.
cAlthough the species is included in the existing MicroSeq full 16S rDNA bacterial
identiﬁcation system database, a 2–3% difference is observed between the 16S
rDNA gene of the species and a closely related species.
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rDNA sequence of the species and that of a
closely related medically important bacterium.
According to our guidelines for 16S rDNA
sequence analysis, if the bacterium belongs to
the ‘?’ or ‘·’ category (e.g. Actinomyces meyeri;
Table 4 and Supplementary Tables 2–4 of refer-
ence [158]), the bacterial species with similar 16S
rDNA sequences will also be known (i.e. A. geor-
giae, A. odontolyticus and A. turicensis; Table 4
and Supplementary Tables 2–4 of reference
[158]). If further species differentiation is neces-
sary, one can look for additional ⁄ supplementary
methods, which may be key phenotypic tests
or sequencing of additional gene loci, to distin-
guish among these species with similar 16S
rDNA sequences. It should be noted that the
cut-offs mentioned are not meant to be used as
criteria for deﬁning new species, but to provide
a clearer meaning for the search results.
Concerning MicroSeq database analysis, a
supplementary note is given to indicate whether
the reason for the inability of the database to
identify the bacterium is due to the species being
not included in the existing database (xa in
Table 4 and Supplementary Tables 2–4 of refer-
ence [158]), or high 16S rDNA sequence similar-
ity (>98% nucleotide identity) to a closely related
species (xb in Table 4 and Supplementary
Tables 2–4 of reference [158]). In the study on
anaerobes, full and 527-bp 16S rDNA sequencing
were capable of identifying 52–63% of 130
anaerobic Gram-positive rods, 72–73% of 86
anaerobic Gram-negative rods, and 78% of
23 anaerobic cocci. Surprisingly, the MicroSeq
databases (version 1.0) were able to identify only
19–25% of 130 Gram-positive anaerobic rods,
38% of 86 Gram-negative anaerobic rods, and
39% of 23 anaerobic cocci. This represents only
45–46% of those that should be conﬁdently
identiﬁed by full-length and 527-bp 16S rDNA
sequencing, indicating that, in order to improve
the usefulness of MicroSeq, bacterial species that
should be conﬁdently identiﬁed by full-length
and 527-bp 16S rDNA sequencing but are not
included in the MicroSeq databases (version 1.0)
should be included. Recently, there has been an
expansion of the MicroSeq databases (ver-
sion 2.0) to include more bacterial species, which
has led to some improvement. At present, we are
performing further studies of aerobic and facul-
tative anaerobic Gram-positive and Gram-nega-
tive bacteria, and the results will be available in
the near future for the development of similar
guidelines.
Despite the extensive analysis, there are still
limitations in these guidelines. First, intraspecies
variation in 16S rDNA sequences was not taken
into account in the analysis. In the evaluation,
only whether there was a signiﬁcant difference
between the 16S rDNA sequence of a particular
species and those of other species was deter-
mined, and a 3% difference was chosen as the
cut-off. Whether there is a high similarity among
the 16S rDNA sequences in different strains of
the same species is difﬁcult to study, because: (i)
16S rDNA sequence information is available for
multiple strains of the same species in only a
minority of species; and (ii) even when 16S
rDNA sequence information is available for
multiple strains of the same species, the strains
are often not well characterized phenotypically,
so the reliability of the sequence information is
difﬁcult to judge. However, despite this limita-
tion, a high degree of conservation of 16S rDNA
sequences for the same species is often assumed,
because most existing results do not indicate
otherwise. On the other hand, for some genera,
the intraspecies variation in 16S rDNA
sequences may be so small that a difference of
3% in the 16S rDNA sequences between two
species may not be necessary for conﬁdent
identiﬁcation. Second, the present study
included only the bacterial species that are
known to be associated with infections. This
was deliberate, because, if those bacterial species
that have never been reported to cause infections
had also been included, some species may have
been classiﬁed as ‘not conﬁdently identiﬁed by
16S rDNA sequencing’ because of the sequence
similarity between a bacterium and another that
has never been reported to cause infection. One
must bear in mind that those species that have
never been reported to be associated with
infections may still have the potential to do so.
Owing to these limitations, we suggest that, in
order to increase the accuracy of 16S rDNA
sequencing for identiﬁcation of pathogenic bac-
teria, it would be necessary to interpret the
results of 16S rDNA sequencing with prelimin-
ary phenotypic test results. Nevertheless, our
data not only facilitate interpretation of sequence
data by inexperienced users in the clinical
microbiology laboratories, but also provide clues
to the potential usefulness of 16S rDNA
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sequencing for different groups of bacteria
before they are chosen for such analysis.
CONCLUDING REMARKS
Not only has 16S rDNA sequencing contributed to
answering some of the most fundamental ques-
tions in biology, but during the last decade this
technology has evolved beyond the research realm
and matured into clinical applications. For the
management of individual patients, accurate and
objective identiﬁcation of clinical isolates, espe-
cially ‘unidentiﬁable bacteria’, rarely encountered
bacteria, slow-growing bacteria and uncultivable
bacteria, has assisted clinicians in the choice of
antibiotics and in determining the duration of
treatment, as well as in infection control measures.
On a population scale, accurate identiﬁcation has
greatly improved our understanding of the epide-
miology of clinical syndromes, and hence has
improved empirical treatment of these. Our under-
standing of all these aspects is further improved by
the discovery of novel genera and species of
bacteria, which has been greatly facilitated by
using 16S rDNA sequencing. Nevertheless, auto-
mation of 16S rDNA sequencing is not yet available
and, despite the wide range of software packages
and databases available, interpretation of results is
often difﬁcult for inexperienced users, due to their
limitations.Hopefully, the generation of guidelines
for the interpretation of 16S rDNA sequences can
make this technology an even more user-friendly
tool in clinical microbiology laboratories in the
coming years.
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